Jacob Sands
Overview
Explore the profile of Jacob Sands including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
934
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wood D, Kazerooni E, Aberle D, Argento C, Baines J, Boer B, et al.
J Natl Compr Canc Netw
. 2025 Jan;
23(1.
PMID: 39819601
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Lung Cancer Screening provide criteria for selecting individuals for screening and offer recommendations for evaluating and managing lung nodules detected...
2.
Sands J, Ahn M, Lisberg A, Cho B, Blumenschein Jr G, Shum E, et al.
J Clin Oncol
. 2025 Jan;
:JCO2401349.
PMID: 39761483
Purpose: Datopotamab deruxtecan (Dato-DXd) is a trophoblast cell-surface antigen-2-directed antibody-drug conjugate with a highly potent topoisomerase I inhibitor payload. The TROPION-Lung05 phase II trial (ClinicalTrials.gov identifier: NCT04484142) evaluated the safety...
3.
Ahn M, Cho B, Felip E, Korantzis I, Ohashi K, Majem M, et al.
Future Oncol
. 2024 Nov;
20(40):3355-3364.
PMID: 39530627
What Is This Summary About?: This is a summary of a phase 2 clinical study called DeLLphi-301. The study looked at how effective and safe a medicine called tarlatamab was...
4.
Ahn M, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, et al.
J Clin Oncol
. 2024 Sep;
43(3):260-272.
PMID: 39250535
Purpose: The randomized, open-label, global phase III TROPION-Lung01 study compared the efficacy and safety of datopotamab deruxtecan (Dato-DXd) versus docetaxel in patients with pretreated advanced/metastatic non-small cell lung cancer (NSCLC)....
5.
Florez N, Patel S, Wakelee H, Bazhenova L, Massarelli E, Salgia R, et al.
Oncologist
. 2024 Sep;
30(2).
PMID: 39237103
Lung cancer is the leading cause of cancer death in the US and globally. The mortality from lung cancer has been declining, due to a reduction in incidence and advances...
6.
Shapira-Frommer R, Niu J, Perets R, Peters S, Shouse G, Lugowska I, et al.
Future Oncol
. 2024 Sep;
20(27):1983-1991.
PMID: 39230120
Vibostolimab, a humanized IgG1 monoclonal antibody, blocks the interaction between TIGIT and its ligands, preventing the immunosuppressive effects of TIGIT. The addition of vibostolimab to the PD-1 inhibitor pembrolizumab has...
7.
Heist R, Sands J, Bardia A, Shimizu T, Lisberg A, Krop I, et al.
Cancer Treat Rev
. 2024 Mar;
125:102720.
PMID: 38502995
Antibody drug conjugates (ADCs) are an emerging class of treatments designed to improve efficacy and decrease toxicity compared with other systemic therapies through the selective delivery of cytotoxic agents to...
8.
Sands J, Subramanian J
Front Oncol
. 2024 Jan;
13:1161931.
PMID: 38221913
Extensive-stage small-cell lung cancer (ES-SCLC) is an aggressive disease with poor 5-year survival. The first-line standard-of-care for ES-SCLC is platinum plus etoposide, along with 1 of the immune checkpoint inhibitors...
9.
Burns L, Tukachinsky H, Raskina K, Huang R, Schrock A, Sands J, et al.
Lung Cancer
. 2023 Dec;
188:107454.
PMID: 38159439
Background: Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is an uncommon subtype of lung cancer believed to represent a spectrum of tumors sharing characteristics of both small cell lung cancer (SCLC) and...
10.
Ahn M, Cho B, Felip E, Korantzis I, Ohashi K, Majem M, et al.
N Engl J Med
. 2023 Oct;
389(22):2063-2075.
PMID: 37861218
Background: Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with previously treated small-cell lung cancer....